The skin care line is the result of a joint marketing venture with industry expert John Maudlin, and the new line has been developed by Lifeline Skin Care, a subsidiary of International Stem Cell.
“The anti-aging market is extremely large, and Lifeline Skin Care is offering something completely new and different,” said Kenneth Aldrich, chairman of Lifeline Skin Care.
The new line is said to have been in development for well over a year and involves a technologically advanced formulation for skin rejuvenation crèmes, developed using ‘parthenogenetic’ stem cells, developed without the use of fertilized embryos by Lifeline Skin Care.
Rejuvenation properties discovered during research
The company says that the rejuvenation properties of the stem cells were discovered during its therapeutic stem cells research, which triggered the development of the skin care line.
The company says that one of the biggest development challenges was finding a way to surround the stem cell proteins with a nano-vesicle. Such a technology has been successfully incorporated into the cells to extend shelf life and enhance the delivery of the product to the skin, the company claims.
“This represents an amazing leap forward in the combination of a variety of cutting edge technologies to yield products that have the potential to find significant consumer acceptance,” said Aldrich.
Product launch date delayed
The company had previously announced that it would be launching the skin care line in October in the US market, but that the launch date has now been put back to November to allow the company to meet anticipated product demand.
The initial product offering will involve 1.5 million potential consumers from the company’s database, combined with the extended database provided by Maudlin.
The company says that following this initial launch, it will follow up by targeting a broader consumer base.